Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading BioCardia Inc. chart...

About the Company

we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

CEO

Peter Altman

Exchange

NASDAQ

Website

http://www.biocardia.com/

$0M

Total Revenue

36

Employees

$8M

Market Capitalization

-0.59

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BCDA News

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

5d ago, source:

Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia’s cell therapy candidate through studies expected to result in FDA approval of an investigational new ...

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

6d ago, source:

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS previously published a New ...

BioCardia spikes after Medicare coverage for cell therapy trial

on MSN ago, source:

BioCardia (BCDA) gains as Medicare approves reimbursement coverage for its Phase 3 CardiAMP Heart Failure II trial for cell ...

Biocardia phase III bolsters cell therapy data in heart failure

15d ago, source: BioWorld

While preparing a follow-on phase III study of its Cardiamp cell therapy, Biocardia Inc. has mined positive interim data at a ...

BioCardia Reports Positive Interim Results From Phase III CardiAMP Cell Therapy Heart Failure Trial

14d ago, source: Business Insider

(RTTNews) - BioCardia, Inc. (BCDA) shares are falling more than 23 percent on Monday morning, despite positive interim reports for its Phase III randomized trial of CardiAMP autologous cell therapy in ...

BioCardia Nabs Medicare Coverage for Heart Failure Cell Therapy Phase III Trial

5d ago, source: precisionmedicineonline

The decision by CMS will allow Medicare-eligible patients in the study to receive coverage for CardiAMP treatment and related services.

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

14d ago, source: Benzinga.com on MSN

Shares of Bitdeer Technologies Group BTDR rose sharply during Monday’s session after the company reported preliminary ...

Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher

on MSN ago, source:

U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, ...

BiomX surges on merger deal with Adaptive Phage

on MSN ago, source:

BiomX (PHGE) stock surges over 120% after a stock-for-stock merger with Adaptive Phage Therapeutics, along with a $50M private placement. Read more here.

Kardia-2 prods Alnylam’s zilebesiran forward, hypertension back

13d ago, source: BioWorld

Roche Holding AG, demonstrated significant systolic blood pressure reductions in patients with mild to moderate hypertension who were part of the Kardia-2 phase II study. A single dose of zilebesiran, ...

BioCardia, Inc.: BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

5d ago, source:

Partnership targets heart failure, the leading cause of death and a condition with limited treatment optionsBioCardia's biotherapeutic delivery system with established safety profile enables minimally ...

BioCardia receives CMS approval for CardiAMP cell therapy confirmatory phase III heart failure study

4d ago, source: Pharmabiz

BioCardia receives CMS approval for CardiAMP cell therapy confirmatory phase III heart failure study: Sunnyvale, California Thursday, March 14, 2024, 13:00 Hrs [IST] Sunnyvale-hea ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...